ArticleBMC cancer2025
Muscle strength and mass as predictors of pancreatic cancer: insights from the UK biobank.
Article in BMC cancer, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
4 citing papers in PubMed.
- Impact of Hypertrophy-Oriented Resistance Training on Muscle Mass and Quality of Life in Patients with Unresectable Pancreatic Cancer (HY-PANC): Study Protocol for a Randomized Controlled Trial.Current protocols · 2026Article
- A bibliometric analysis of the association between ultrasound and sarcopenia: Trends, networks, and future directions.Medicine · 2026Article
- Article
- Beyond aggregate volume-Accelerometer-derived activity phenotypes reveal a decoupling of lean mass and function: A cross-sectional study.Science progressArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
Abstract
backgroundWhile sarcopenia is associated with adverse pancreatic cancer (PC) outcomes, prospective evidence linking muscle health to PC risk remains limited. This study aimed to prospectively investigate the associations of grip strength and muscle mass with incident PC risk in the UK Biobank cohort.
methodsAmong 363,693 UK Biobank participants, grip strength (kg) and bioelectrical impedance analysis (BIA)-derived muscle mass (weight-normalized) were measured. Cox proportional hazards models, adjusted for age, sex, lifestyle factors, and metabolic syndrome components, assessed PC risk over a median 13.7-year follow-up.
resultsHigher muscle mass (HR = 0.86, 95% Confidential Interval [CI]:0.78-0.95) and grip strength (HR = 0.90, 95% CI:0.83-0.98) demonstrated linear inverse associations with PC risk showing sex-specific divergence: muscle mass reduction conferred stronger protection in men (HR = 0.84, 95% CI:0.74-0.96), whereas grip strength showed greater impact in women (HR = 0.84, 95% CI:0.74-0.96). Subgroup analyses revealed that improved grip strength reduced PC risk in diabetics (HR = 0.89, 95% CI:0.80-0.99), while obese individuals benefited from both enhanced grip strength (HR = 0.95, 95% CI:0.90-0.99) and muscle mass (HR = 0.88, 95% CI:0.82-0.94). Population-attributable fraction estimates suggest 5-12% of PC cases could be prevented through muscle health interventions.
conclusionThese findings highlight an association between improved physical capability and reduced PC risk, supporting the adoption of sex-specific preventive strategies-prioritizing muscle mass augmentation in men and grip strength enhancement in women, particularly in high-risk metabolic subgroups. By characterizing sarcopenia as an independent risk factor, this study underscores the imperative to integrate muscle preservation into pancreatic cancer prevention paradigms.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.